Timothy Roe

Parsing Beijing Med-Pharm Corp.'s Latest Results

Good point 142619. Revs and earnings should improve as these deals are folded in. BJGP is at a bit of a tough spot as they digest the acquisitions and incorporate the individual financials without the benefit of increased operational efficiencies that will likely be seen in coming quarters. Increasing the number of products that they can push through their newly built distribution "pipeline" should also help margins.